SUPRIYA is on track to delivering revenue of Rs 1,000 cr by FY27 while maintaining EBITDA margin of 28-30%. The revenue CAGR of 20%+ for FY23-27 could provide opportunity for the stock.
Share this post
Supriya Lifescience: PAT growth of 59% …
Share this post
SUPRIYA is on track to delivering revenue of Rs 1,000 cr by FY27 while maintaining EBITDA margin of 28-30%. The revenue CAGR of 20%+ for FY23-27 could provide opportunity for the stock.